Listeria-Based Immunogenic Compositions And Methods Of Use Thereof in Cancer Prevention And Treatment
AssigneeAdvaxis, Inc.
InventorsRobert Petit, Michael F. Princiotta, Kyle Perry
Life of this patent
Estimating the term…
Abstract
Disclosed herein are recombinant Listeria strains comprising nucleotides encoding two or more heterologous antigens each fused to a truncated LLO, an N-terminal ActA or a PEST-sequence, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
Claims34
A recombinant Listeria strain comprising a nucleic acid molecule comprising a first open reading frame encoding a fusion polypeptide, the fusion polypeptide comprising a truncated listeriolysin O (LLO), a truncated ActA, or a PEST amino acid sequence fused to a prostate specific antigen (PSA) or an immunogenic fragment thereof, a survivin antigen or an immunogenic fragment thereof, a prostate specific G-protein coupled receptor (PSGR) antigen or an immunogenic fragment thereof, and a hepsin antigen or an immunogenic fragment thereof.
(canceled)
(canceled)
(canceled)
32-40. (canceled)
42-80. (canceled)
Dependencies are inferred from the claim text.